(0.04%)
(-1.51%)
PDF TOP10 (Weighting Descending%)
Jiangsu Hengrui Pharmaceuticals Co Ltd
6.73%Innovent Biologics Inc
5.43%WuXi AppTec Co Ltd
3.9%Shanghai RAAS Blood Products Co Ltd
3.36%Shenyang Xingqi Pharmaceutical Co Ltd
3.35%Wuxi Biologics Cayman Inc
3.05%Sino Biopharmaceutical Ltd
2.98%Beijing Tiantan Biological Products Corp Ltd
2.72%Akeso Inc
2.49%SOLACTIVE CHINA BIOTECH INDEX CNH TRS 230209-12
2.37%Related document
| Fund Name | TIGER China Biotech Solactive |
|---|---|
| Legal Structure | Investment Trust, Open-end, Exchange-traded fund |
| Benchmark Index | Solactive China Biotech Index |
| Total Expense Ratio | 0.49% |
| Dividend | Last business day of Jan, Apr, Jul, Oct or end of fiscal year |
| Manager | Mirae Asset Global Investments |
|---|---|
| Trustee | Citi Bank |
| Investment Methodology | Full Replication or Optimization |
| Stock Exchange | Korea Exchange |
|---|---|
| Stock Code | 371470 |
| Bloomberg | 371470 KS |
| Currency Denomination | Korean Won |
| Index Multiplier | 1X |
| Pricing | 10,000 Won |
| Board Lot | 1 Share |
| Creation Unit | 40,000 shares |
| First Trading Date | 2020-12-08 |
| Authorized Participants | KB Securities ,NH Investment & Securities ,Daishin Securities ,Meritz Securities ,Mirae Asset Securities ,Samsung Securities ,Shinhan Securities ,eBEST Investment & Securities ,Kiwoom Securities ,Korea Investment & Securities |
| Liquidity Providers | KB Securities ,NH Investment & Securities ,Daishin Securities ,Meritz Securities ,Mirae Asset Securities ,Samsung Securities ,eBEST Investment & Securities ,Kiwoom Securities ,Korea Investment & Securities |
| Transaction Tax | Exempted |
| Short Selling | Allowed and exempted from up-tick rule |
| IOPV Calculation | Every 10 seconds, disclosed on the KRX website |
| TIGER website | www.tigeretf.com |
| KRW website | http://global.krx.co.kr/main/main.jsp |